美股市场个股详情
XBI SPDR标普生物科技ETF
- 89.880
- +1.740+1.97%
收盘价 05/13 16:00 (美东)
90.760最高价89.000最低价
90.760最高价89.000最低价1100.03万股成交量89.060今开88.140昨收9.90亿成交额14.73%换手率--市盈率(静)7470.00万总股本103.52052周最高--市净率67.14亿流通值63.78952周最低0.02股息TTM7470.00万流通股174.706历史最高0.02%股息率TTM2.00%振幅21.378历史最低90.008平均价1股每手
Interesting list of name for the incoming CPI..
$诺瓦瓦克斯医药(NVAX.US)$ $SPDR标普生物科技ETF(XBI.US)$ $标普500指数(.SPX.US)$
2 biggest deals this yr:
$福泰制药(VRTX.US)$ paid $4.9 bil for $Alpine Immune(ALPN.US)$
$吉利德科学(GILD.US)$ paid $4.3 bil for $CBAY
Bolt-on deals likely to continue to be the dominant story in 2024, which means we could also see more of this trend...
Last yr 84% of M&A deal dollars were for Biotechs w/ Phase 3 & Marketed assets,
In the first four months of 2024 56% of M&A deal dollar went towards P...
$辉瑞(PFE.US)$ $德纳维制药(DVAX.US)$ $沙尘暴黄金(SAND.US)$ $施贵宝(BMY.US)$ $SPDR标普生物科技ETF(XBI.US)$
Assumptions: Overall market is stable and not turning into bear market; US economy no recession; Better to start rate cut in 2024.
$纳斯达克综合指数(.IXIC.US)$ $标普500指数(.SPX.US)$
M&A in Q1 alone totaled 12 deals for $19.2 bil which is close to the 10 deals for $21.9 bil in all the 1H of 2023...
But one big caveat of this chart, it doesn't include $辉瑞(PFE.US)$ 's $43 bil deal for $SGEN announced in Mar 2023 but didn't close until Dec bc of an FTC challenge,
The biggest biotech M&A deal so far this yr was $吉利德科学(GILD.US)$ 's $4.3 b...
Observations from $VINC (-60% AH):
1- When companies tout "strong safety profile", often means efficacy is a big fat zero
2- Phrases like "dose dependent clinical activity" set the bar low
3- "Promising" doesn't necessarily refer to SP
Stay skeptical, my friends.
Mike on biotech's correlation with interest rates:
"Biotech is essentially a call option on $20+年以上美国国债ETF-iShares(TLT.US)$
Biotech bulls need inflation and rates to move lower for resumption of a real bull market.
XBI is likely to remain range-bound - or worse - until inflation convincingly moves lower.
Hopefully we can grind out reasonable returns in the meantime by buying the right stocks, but we will b...
$默沙东(MRK.US)$ x $Immunovant(IMVT.US)$
$礼来(LLY.US)$ x $Cytokinetics(CYTK.US)$ (and soon)
$再生元制药公司(REGN.US)$ x $Apellis Pharmaceuticals(APLS.US)$ (panache & brash)
$吉利德科学(GILD.US)$ x % $Madrigal Pharmaceuticals(MDGL.US)$ (liver king)
$施贵宝(BMY.US)$ x $Iovance Biotherapeutics(IOVA.US)$ (cell Tx boost needed)
$礼来(LLY.US)$ x $Merus(MRUS.US)$ (partner n...
– Private Funding –
Clasp Therapeutics
🏦 Launched w/ $150M Series A financing from several investors to develop their T-cell engagers (TCE) pipeline.
Capstan Therapeutics
🏦 Closed $175M Series B financing led by RA Capital Management to support the advancement of CPTX2309, their in vivo CAR-T product candidate.
Engrail Therapeutics
🏦 Closed $157M Series B financing round to advance the development of their therapies.
Pan...
暂无评论